chevron_leftBack
As of 12 June 2026, Medicenna Therapeutics Corp. has a market cap of $34.01M USD, ranking #33357 globally and #1095 in Canada.
It ranks #3009 in the Healthcare sector, and #582 in the Biotechnology industry.
Key Stats
Market Cap
$34.01MUSD
47.55M CAD
Enterprise Value
$26.57MUSD
37.07M CAD
EBITDA (TTM)
-$15.99MUSD
-22.31M CAD
Net Income (TTM)
-$9.29MUSD
-12.99M CAD
PB Ratio
7.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Fahar Merchant
open_in_new
Employees
18
Website
medicenna.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 5.3% | 1.7% | -4.8% | -33% | -63% | -45% |
Upcoming Earnings
Earnings Date
Fri, Jun 26
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
MDNA
Medicenna Therapeutics Corp
ISIN: CA58490H1073
Shares Out.:
Shares Outstanding:
68.737M1
Shares Float:
50.654M2
|
0.6000 CAD | |
|
MDNA
Medicenna Therapeutics Corp
ISIN: CA58490H1073
|
0.4250 CAD | |
|
MDNAF
Medicenna Therapeutics Corp
ISIN: CA58490H1073
Shares Out.:
Shares Outstanding:
68.727M1
Shares Float:
53.466M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.7290 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AUPH
|
$1.99B
6K%
|
7.4
|
|
NASDAQ: ABCL
|
$1.16B
3K%
|
-
|
|
TSX: EPRX
|
$429.8M
1K%
600.89M CAD
|
-
|
|
TSXV: NGEN
|
$293.4M
763%
410.19M CAD
|
-
|
|
NEO: CYBN
|
$252.59M
643%
353.13M CAD
|
-
|
|
TSX: CRDL
|
$148.84M
338%
208.08M CAD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
536K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
470K%
|
19.0
|
|
EBR: ARGX
|
$47.8B
140K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
132K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
124K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.17B
124K%
33.71B CHF
|
37.2
|
chevron_leftBack